The HMGN3 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the A-549 human lung adenocarcinoma cell line. This heterogeneous cell pool carries diverse loss-of-function mutations in the HMGN3 gene, enabling functional studies of this nucleosome-binding protein without clonal isolation. The polyclonal format preserves genetic diversity, making it suitable for population-level assays and pooled screening approaches. Loss of HMGN3 serves as a model for investigating transcriptional regulation, chromatin remodeling, and signal transduction pathways.
The host A-549 cell line originates from a 58-year-old male patient with lung adenocarcinoma and is a well-characterized model for alveolar epithelial cells and non-small cell lung cancer. These adherent cells express typical lung epithelial markers and exhibit robust responses to growth factors and cytokines. A-549 cells are extensively utilized in oncology drug discovery, toxicology, and mechanistic cancer signaling studies, particularly those examining insulin, TGF-??, and Wnt pathways, making them an optimal platform for dissecting the functions of chromatin regulators such as HMGN3.
HMGN3 is a high mobility group nucleosome-binding protein that directly associates with histone H3, modulating chromatin compaction and global gene expression. In insulin-responsive contexts, HMGN3 acts downstream of INSR and AKT to facilitate PKC??-dependent GLUT4 (SLC2A4) translocation, a critical step in glucose homeostasis. Within TGF-?? signaling, HMGN3 interacts with receptor-regulated SMAD2 and SMAD3 and is a substrate for CK2??, which fine-tunes its chromatin affinity and SMAD-mediated transcription. HMGN3 also cross-talks with Wnt/??-catenin signaling, potentially influencing TCF/LEF transcriptional outputs. Consequently, HMGN3 ablation impairs insulin-stimulated metabolic responses, attenuates TGF-??-induced SMAD activation, and alters Wnt target gene expression, leading to dysregulated cell metabolism, proliferation, and EMT.
Introducing HMGN3 knockout into A-549 cells creates a powerful system to explore how chromatin architecture orchestrates oncogenic phenotypes. This model allows researchers to examine changes in glucose uptake, migratory capacity, and EMT programs driven by simultaneous insulin, TGF-??, and Wnt pathway perturbations. The polyclonal nature of the population mirrors tumor heterogeneity, enabling bulk analyses of phenotypic plasticity and signaling crosstalk that are central to lung adenocarcinoma progression and metastasis.
This knockout population supports a broad spectrum of applications: Western blot confirms HMGN3 depletion, RT-qPCR quantifies GLUT4 transcript levels, ChIP-qPCR maps HMGN3 genome occupancy, and RNA-seq reveals global transcriptomic rewiring. Flow cytometry assesses cell cycle distribution, while migration and invasion assays measure metastatic potential. Insulin signaling capacity is gauged by p-AKT ELISA, and TGF-?? pathway activity by p-SMAD2 detection. Metabolic glucose uptake assays further complement functional studies. This model thus serves type 2 diabetes investigations, lung adenocarcinoma biology, chromatin structure-function research, and drug target validation. For further information, contact Ascent Research.
